New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

New York State Common Retirement Fund grew its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 49.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,581 shares of the company's stock after buying an additional 11,090 shares during the quarter. New York State Common Retirement Fund owned 0.07% of Axsome Therapeutics worth $3,917,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. bought a new position in Axsome Therapeutics during the first quarter worth $31,000. Raiffeisen Bank International AG acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at $51,000. Aquatic Capital Management LLC bought a new stake in Axsome Therapeutics in the fourth quarter worth about $76,000. GF Fund Management CO. LTD. bought a new stake in Axsome Therapeutics in the fourth quarter worth about $86,000. Finally, Bank Hapoalim BM bought a new stake in Axsome Therapeutics in the first quarter worth about $204,000. 81.49% of the stock is currently owned by institutional investors.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the sale, the director directly owned 50,387 shares in the company, valued at approximately $5,314,316.89. The trade was a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Mark L. Jacobson sold 25,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the sale, the chief operating officer owned 5,783 shares in the company, valued at approximately $638,674.52. This represents a 81.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,437 shares of company stock worth $9,834,215 over the last three months. 22.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

AXSM has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a research note on Monday, April 7th. They issued a "buy" rating and a $200.00 price target on the stock. Wells Fargo & Company reissued an "overweight" rating and issued a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Mizuho lifted their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research note on Thursday, March 27th. Cantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Finally, Morgan Stanley assumed coverage on Axsome Therapeutics in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 price target on the stock. One research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of "Buy" and an average target price of $172.33.

Axsome Therapeutics Stock Performance

Shares of AXSM stock traded down $1.38 during trading hours on Thursday, reaching $104.98. 222,683 shares of the company's stock were exchanged, compared to its average volume of 794,405. Axsome Therapeutics, Inc. has a fifty-two week low of $72.21 and a fifty-two week high of $139.13. The stock has a market capitalization of $5.17 billion, a P/E ratio of -18.19 and a beta of 0.46. The business has a fifty day moving average price of $106.53 and a 200-day moving average price of $109.56. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.